The National Institutes of Health has awarded $10 million to three groups to advance a technology for the painless, self-administration of flu vaccine using patches containing tiny microneedles that dissolve into the skin.
A new Medicare drug plan with the lowest upfront cost in the country may not be for everyone, experts say. Medicare's open enrollment season just started, and the plan from insurer Humana and retail giant Walmart is getting attention.
An experimental Merck drug safely boosted good cholesterol to record highs while dropping bad cholesterol to unprecedented lows in a study that stunned researchers and renewed hopes for an entirely new way of lowering heart risks.
Federal health experts voted in favor of the first new drug to treat Lupus in over 50 years, setting aside concerns that the experimental therapy does not work in some key patient groups, including African-Americans.
Some people who couldn't get their blood pressure under control despite taking a fistful of pills every day found relief from an experimental treatment that shows promise as a permanent fix for the condition.
Eli Lilly and Company announced that the trial on the validity of the compound patent for Alimta before the U.S. District Court for the District of Delaware ended this afternoon with a ruling from the court that judgment would be entered in Lilly's favor.
Protea Biosciences, Inc., a leading developer of technology for biomolecular analysis, announced that the company has completed an expansion of its GLP Bioanalytical Laboratory, including the introduction of quantitative proteomics mass spectrometry services.
A pediatric immunologist at collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.
A drug used decades ago to treat high blood pressure has been shown to improve learning and memory in mouse models of Alzheimer's disease, according to a new study by researchers at the National Institute on Aging.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase 3 study for Orazol. If successful, the Phase 3 study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure.
Results from an observational substudy from TRITON—TIMI 38 showed that patients treated with Effient prior to coronary artery bypass graft surgery had a reduced overall mortality rate compared to patients treated with Plavix.
Avantor Performance Materials announced that it is renaming its Mallinckrodt Chemicals brand product line Macron Chemicals, as the company transitions away from its former Mallinckrodt Baker identity.
Optivia Biotechnology Inc. announced that it and the University of California, San Francisco, have received a SBIR grant to develop an innovative system for characterizing the role transporter proteins play in the disposition of drugs by the liver.
ReNeuron Group plc announces that the first patient has been treated with its ReN001 stem cell therapy for stroke in a ground-breaking UK clinical trial. PISCES is the world’s first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients.
Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers.